• 1
    Dailey G. A timely transition to insulin: identifying Type 2 diabetes patients failing oral therapy. Formulary 2005; 40: 114130.
  • 2
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 2003; 26: 30803086.
  • 3
    Yki-Järvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in Type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 13641369.
  • 4
    Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC et al. Plasma glucose levels throughout the day and HbA1c interrelationships in Type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001; 24: 20232029.
  • 5
    Monami M, Lamanna C, Lambertucci L, Longo R, Cocca C, Addante F et al. Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes. J Endocrinol Invest 2006; 29: 619624.
  • 6
    Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736742.
  • 7
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in Type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554559.
  • 8
    Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled Type 2 diabetes mellitus. Endocr Pract 2010; 16: 588599.
  • 9
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for Type 2 diabetes. Diabetes Care 2005; 28: 254259.
  • 10
    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K et al. Insulin glargine or NPH combined with metformin in Type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442451.
  • 11
    Sanofi-Aventis. Lantus Versus Humalog Mix as Add-On Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment. 2001. Trial identifier: NCT01336751. Available at Last accessed 11 November 2011.